TheEdgeResearch
Home / Stocks / ATGGF

Actinogen Medical Limited (ATGGF)

OTC Healthcare Biotechnology
$0.33 ▲ +0.00%
Market Cap
$1.28B
Sector
Healthcare
Industry
Biotechnology
Beta
0.89
52-Wk Range
0.0008-1
CEO
Steven G. Gourlay
Country
AU
Currency
USD

Actinogen Medical Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.33, up 0.00% on the session, giving a market capitalisation of $1.28B. On trailing twelve-month figures it carries a trailing P/E of -1.88, a net margin of 0.0%. Its beta of 0.89 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.88
Price / Sales
0.00
Price / Book
1.39
EV / EBITDA
-0.83
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.22
Current ratio
3.45
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
6
IPO date
2018-09-18
Headquarters
Sydney, NSW, AU
About Actinogen Medical Limited

Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.

More research on ATGGF
ATGGF technical analysis ATGGF TheEdge Score Compare against peers
Open full interactive analysis & DCF →